Scandinavian Biopharma expand their portfolio with Coagadex® – the first and only tailormade treatment for the rare bleeding disorder ‘factor X deficiency’

Scandinavian Biopharma has entered into a distribution agreement with Bio Products Laboratory Limited (BPL), a leading manufacturer of plasma-derived protein therapies, for their unique factor X deficiency product Coagadex®. Coagadex® is the first and only tailormade treatment for factor X deficiency bleeding disorder in Europe. Coagadex® is indicated for the treatment and prophylaxis of bleeding […]